We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Faron Pharmaceuticals Oy | LSE:FARN | London | Ordinary Share | FI4000153309 | ORD NPV (DI) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 12.50 | 6.94% | 192.50 | 20,536 | 15:54:23 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 190.00 | 195.00 | 192.50 | 180.00 | 180.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | EUR | EUR -30.94M | EUR -0.2958 | -6.51 | 188.32M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:20:20 | O | 5,000 | 199.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 02/12/2024 | 08:00 | UK RNS | Faron Pharmaceuticals Oy Interactions with UK Regulatory Authorities |
| 27/11/2024 | 11:29 | ALNC |  Faron announces promising findings from blood cancer drug trial |
| 27/11/2024 | 07:00 | UK RNS | Faron Pharmaceuticals Oy Positive Phase 2 Interim Results from BEXMAB Trial |
| 11/11/2024 | 07:00 | UK RNS | Faron Pharmaceuticals Oy Targeting Soluble Clever-1 for Autoimmune Diseases |
| 05/11/2024 | 07:00 | UK RNS | Faron Pharmaceuticals Oy Shareholders’ Nomination Board |
| 22/10/2024 | 06:00 | UK RNS | Faron Pharmaceuticals Oy Faron’s Capital Markets Day 2024 |
| 07/10/2024 | 06:00 | UK RNS | Faron Pharmaceuticals Oy Faron announces Capital Markets Day |
| 30/8/2024 | 06:00 | UK RNS | Faron Pharmaceuticals Oy Grant of options |
| 27/8/2024 | 10:08 | ALNC | Faron Pharma shares surge as US FDA grants fast track designation |
| 27/8/2024 | 06:00 | UK RNS | Faron Pharmaceuticals Oy Faron 2024 Half-Year Financial Results |
Faron Pharmaceuticals Oy (FARN) Share Charts1 Year Faron Pharmaceuticals Oy Chart |
|
1 Month Faron Pharmaceuticals Oy Chart |
Intraday Faron Pharmaceuticals Oy Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 27/8/2024 | 14:31 | Respite for ARDS sufferers | 1,624 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:42:46 | 199.00 | 5,000 | 9,950.00 | O |
| 16:20:21 | 194.00 | 513 | 995.22 | O |
| 16:08:19 | 191.00 | 2,500 | 4,775.00 | O |
| 16:04:00 | 191.00 | 647 | 1,235.77 | O |
| 15:54:24 | 195.00 | 300 | 585.00 | O |
| Top Posts |
|---|
Posted at 03/12/2024 08:20 by Faron Pharmaceuticals Oy Daily Update Faron Pharmaceuticals Oy is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FARN. The last closing price for Faron Pharmaceuticals Oy was 180p.Faron Pharmaceuticals Oy currently has 104,620,000 shares in issue. The market capitalisation of Faron Pharmaceuticals Oy is £201,393,500. Faron Pharmaceuticals Oy has a price to earnings ratio (PE ratio) of -6.51. This morning FARN shares opened at 180p |
Posted at 27/8/2024 14:31 by citys2874 FARN AND INDI BREAKING OUT NOW |
Posted at 18/3/2024 12:20 by pdt I don't usually gamble but decided to make a small punt on today's news.It should be sufficient to enable them to get the £30m funding they need which in turn will enable them to get more results later in the year and successfully out licence. Result being a share price a multiple of todays. Alternatively they will fail to get funding or have future poor trial outcomes and I will lose 100% of today's punt. Either way on a 12 month time horizon I should know one way or the other. |
Posted at 23/4/2022 17:56 by share23 Faron latest presentation. CFO mentions that they have hired new VP of investor relations to New York and that they are making Faron Wallstreet ready. Are they getting ready for an IPO to Nasdaq, New York? (around 4:00 minutes)Additionally CEO talks about potential licensing deal for Bexmarilimab and refers to other deals that have been made in the area which are billion-dollar milestone deals. CEO also says after mentioning the billion dollar deals: Happy to say there are number of companies discussing with us (around 19:00 minutes).Can't believe this company is so under the radar with so low share price.https://faron. |
Posted at 17/11/2020 12:33 by sharesoc The presentation packs and recording from our webinar with Faron Pharma on 3rd Nov can be found here for full members to view: To access the presentation, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hxxps://www.sharesoc Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the presentation (and presentations on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hxxps://www.sharesoc |
Posted at 25/10/2020 13:29 by sharesoc Potential investors and current shareholders may be interested in our webinar with Faron Pharmaceuticals (FARN), 3 November 2020 |
Posted at 16/10/2020 09:59 by toffeeman This is Farn IV I think“ Solidarity’s “most disappointing results,” however, are those for interferon-beta, says Topol. Mortality among the 2050 people who received that drug (either alone or in combination with lopinavir/ritonavir) was 11.9%, versus 10.5% in the control group". |
Posted at 28/9/2020 08:45 by raldo Interesting price action today - volume picking up a bit |
Posted at 24/7/2020 08:24 by ih_752952 DNL =3x Approvals expected during next 2 months including an Orphan Drug with FDA decision on September 29 = CHEAPEST UK Biotech a potential 500%++ GEMDiurnal Group (DNL) = MCap £38 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping giant here .GL Market Cap £38 million Cash £15 million Price 30p Alkindi approval in Australia expected this Quarter Alkindi approval in Israel expected this Quarter FDA decision for Alkindi on September 29 EMA Decision for Chronocort expected in early Q1 2021 |
Posted at 20/7/2020 16:16 by diversification They did say that, but was that an opinion or stated fact backed up with trial results? I'm not looking to argue with you, I also managed to financially benefit from the rise in SNG, but the conference call was less than impressive imo. Good luck with your investment, I assume you also hold FARN to be positing here? |
Posted at 20/2/2020 11:59 by bioking DNL about to explode , Institutional investor added 1 million shares this week . LOTS of BIG NEWS around the corner =10+ BAGGER GEM RALLLYYYYYYYYYYYYDiurnal (DNL) Market Cap £27 M Price: 31p Upcoming Catalysts: MAA-Acceptance for Chronocort in February/March 2020 Alkindi approval in Israel expected in 2Q 2020 Alkindi approval in Australien expected in 2Q 2020 US-Partnership for Alkindi & Chronocort expected in 1H 2020 Alkindi & Chronocort Partnership for Asia für Japan und China US-Approval for Alkindi expected in 4Q 2020 EU Approval for Chronocort expected in 4Q/1Q 2020/21 Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
